Key result
Higher glycaemic variability was significantly associated with an elevated risk of mortality in patients with heart failure (RR 2.18; 95% CI 1.61-2.96; P<0.001).
Why the study?
Fluctuations in blood glucose may increase the risk of unfavourable outcomes in cardiovascular disease, but the relationship between glycaemic variability and mortality in heart failure needed evaluation.
Does higher glycaemic variability increase mortality in patients with heart failure?
Meta-Analysis (n=76,843)
Yes
Does higher glycaemic variability increase mortality in patients with heart failure?
Relative Risk: 2.18 (95% CI 1.61–2.96)
p-value: p=<0.001
High glycaemic variability is significantly associated with an increased risk of mortality in patients with heart failure, regardless of diabetic status.
May warrant GV monitoring to stratify HF mortality risk; leaves open whether reducing variability improves outcomes.
Recent findings indicate that fluctuations in blood glucose could potentially increase the risk of unfavourable outcomes in individuals with cardiovascular conditions. The objective of the research was to assess the correlation between glycaemic variability (GV) and the mortality of patients with heart failure (HF) through a comprehensive review and meta-analysis. Longitudinal follow-up studies comparing the mortality risk between HF patients with higher and lower GV were identified by searching Medline, Embase, Web of Science, and Cochrane Library databases. The results were combined using a random-effects model that accounted for the potential variability. The meta-analysis included nine cohort studies involving 76 843 patients diagnosed with HF, out of which 35 853 patients died within a follow-up period of up to 86 months. The combined findings indicated that a significant increase in GV was linked to an elevated risk of mortality in patients with HF during the follow-up period (RR 2.18, 95% CI 1.61 to 2.96, P < 0.001, I2 = 83%). The relationship between GV and mortality in HF patients was not significantly influenced by the patients' diabetic status (diabetic or non-diabetic), type of GV (acute or long-term GV), study design (prospective or retrospective), country of the study (Asian or non-Asian), follow-up durations, or the scores of study quality (P-values for subgroup differences all >0.05). A high GV could be a risk factor of mortality of patients with HF.
No takes yet. Share an insight, caveat, or question.
Fu et al. (2024) conducted a meta-analysis in Heart failure (n=76,843). Higher glycaemic variability vs. Lower glycaemic variability was evaluated on Mortality (RR 2.18, 95% CI 1.61 to 2.96, p=<0.001). Higher glycaemic variability was significantly associated with an elevated risk of mortality in patients with heart failure (RR 2.18; 95% CI 1.61-2.96; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: